Lessee, Operating Lease, Liability, Undiscounted Excess Amount of Mersana Therapeutics, Inc. from 31 Dec 2019 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
Mersana Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD history and change rate from 31 Dec 2019 to 31 Dec 2024.
  • Mersana Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending 31 Dec 2024 was $349,000, a 67% decline year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Change (%)

Mersana Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $349,000 -$720,000 -67% 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q4 2023 $1,069,000 -$1,058,000 -50% 31 Dec 2023 10-K 28 Feb 2024 2023 FY
Q4 2022 $2,127,000 -$1,511,000 -42% 31 Dec 2022 10-K 28 Feb 2023 2022 FY
Q4 2021 $3,638,000 -$216,000 -5.6% 31 Dec 2021 10-K 28 Feb 2022 2021 FY
Q3 2021 $4,005,000 -$160,000 -3.8% 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 $4,387,000 -$97,000 -2.2% 30 Jun 2021 10-Q 06 Aug 2021 2021 Q2
Q1 2021 $3,549,000 -$1,262,000 -26% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $3,854,000 +$3,668,000 +1972% 31 Dec 2020 10-K 26 Feb 2021 2020 FY
Q3 2020 $4,165,000 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $4,484,000 30 Jun 2020 10-Q 07 Aug 2020 2020 Q2
Q1 2020 $4,811,000 31 Mar 2020 10-Q 08 May 2020 2020 Q1
Q4 2019 $186,000 31 Dec 2019 10-K 28 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.